Work

621P Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A update

Year: 2020

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2020.08.880

Authors: J.A. Arranz Arija, E.Y. Yu, J.M. Piulats, G. Gravis, B. Laguerre, S. Oudard, P.C. Fong, M.P. Kolinsky, M. Augustin, T. Todenhöfer, A.E. Kam, H. Gurney, A. Tafreshi, M. Retz, W.R. Berry, N. Mar, H. Wu, P. Qiu, C. Schloss, J.S. de Bono

Institutions: Hospital General Universitario Gregorio Marañón, University of Washington, Institut Català d'Oncologia, Institut Paoli-Calmettes, Centre Eugène Marquis, Hôpital Européen Georges-Pompidou, Auckland City Hospital, Cross Cancer Institute, Paracelsus Medizinische Privatuniversität, Rush University Medical Center, Macquarie University, University of Wollongong, TUM Klinikum, Technical University of Munich, Merck & Co., Inc., Rahway, NJ, USA (United States), Royal Marsden NHS Foundation Trust, Royal Marsden Hospital

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: Merck Sharp and Dohme

OpenAlex ID: W3089315029

FWCI: 0.705

Cites:

Cited by: 5

Related to: 10